EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia

Srishti Shrestha, Xiaoqian Zhu, B Gwen Windham, Kevin J Sullivan, Priya Palta, Rebecca F Gottesman, Russell P Tracy, Clifford R Jack, Petrice M Cogswell, Prashanthi Vemuri, Sudha Seshadri, Thomas H Mosley und 2 weitere

Alzheimer's & Dementia · 2026

DOI: 10.1002/alz.71422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Srishti Shrestha und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Memory Impairment and Neurodegenerative Dementia (MIND) Center, University of Mississippi Medical Center, Jackson, Mississippi, USA. Hauptthemen laut MEDLINE: Biomarkers, Neuroglia, Cognitive Dysfunction, Dementia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Prospective studies of blood‐based biomarkers reflecting pathogenic processes, other than Alzheimer‐specific pathologies, that contribute to dementia in diverse cohorts are lacking. METHODS We jointly fitted linear mixed‐effect models and proportional hazards models to examine associations of midlife glial fibrillary acidic protein (GFAP), chitinase‐3‐like protein 1 (YKL‐40), soluble cluster of differentiation‐14 (sCD14), neurofilament light chain (NfL), total tau (t‐tau), and ubiquitin C‐terminal hydrolase L1 (UCHL1) levels in serum (collected in 1993 to 1995) with cognitive decline and incident dementia (ascertained over 29 years through 2022) in the community‐based Atherosclerosis Risk in Communities Study. sCD14 and YKL‐40 were measured in 3082 participants and the other four biomarkers in 1766 participants. RESULTS Higher serum GFAP, YKL‐40, sCD14, and NfL were associated with faster cognitive decline and elevated dementia rate (e.g., 1 standard deviation [SD] higher log‐base2 YKL‐40 was associated with −0.11SD faster 25‐year cognitive decline (95% confidence interval [CI]: −0.15,−0.07) and 45% higher dementia hazard (hazard ratio [HR]: 1.45 [95% CI: 1.25, 1.68]). Higher t‐tau and UCHL1 were also associated with faster cognitive decline. DISCUSSION Midlife blood biomarkers reflecting glial and neuronal dysfunction and neuroinflammation are associated with early cognitive impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersNeurogliaCognitive DysfunctionDementiaNeuronsHumansMaleFemaleChitinase-3-Like Protein 1Glial Fibrillary Acidic ProteinAgedUbiquitin ThiolesteraseMiddle AgedNeurofilament Proteinstau ProteinsProspective StudiesLipopolysaccharide ReceptorsIncidence

Stichwörter der Autor:innen

ARIC studyGFAPNfLUCHL1YKL‐40blood‐based biomarkerschitinase‐3‐like protein 1cognitive declineglial fibrillary acidic proteinincident dementianeurofilament light chainsCD14soluble cluster of differentiation‐14ubiquitin C‐terminal hydrolase L1

Substanzen

BiomarkersChitinase-3-Like Protein 1Glial Fibrillary Acidic ProteinCHI3L1 protein, humanUbiquitin ThiolesteraseGFAP protein, humanNeurofilament Proteinstau ProteinsLipopolysaccharide ReceptorsUCHL1 protein, human

Autor:innen und Institutionen

  • The Memory Impairment and Neurodegenerative Dementia (MIND) Center, University of Mississippi Medical Center, Jackson, Mississippi, USA.
  • Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Stroke Branch, National Institute of Neurological Disorders and Stroke Intramural Research Program, Bethesda, Maryland, USA.
  • Department of Pathology and Laboratory Medicine and Biochemistry, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.
  • Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, Texas, USA.

Förderung

  • NIH HHS
  • NHLBI NIH HHS
  • NINDS NIH HHS
  • NIA NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health
  • National Institute on Aging
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Shrestha, S., Zhu, X., Windham, B. G., Sullivan, K. J., Palta, P., Gottesman, R. F., Tracy, R. P., Jack, C. R., Cogswell, P. M., Vemuri, P., Seshadri, S., Mosley, T. H., Griswold, M. E., & Fornage, M. (2026). Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71422

Vancouver

Shrestha S, Zhu X, Windham BG, Sullivan KJ, Palta P, Gottesman RF, et al. Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71422

BibTeX
@article{Shrestha2026,
  author = {Shrestha, Srishti and Zhu, Xiaoqian and Windham, B Gwen and Sullivan, Kevin J and Palta, Priya and Gottesman, Rebecca F and Tracy, Russell P and Jack, Clifford R and Cogswell, Petrice M and Vemuri, Prashanthi and Seshadri, Sudha and Mosley, Thomas H and Griswold, Michael E and Fornage, Myriam},
  title = {Associations of blood biomarkers of glial cell dysfunction and neuronal injury with future cognitive decline and incident dementia},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  doi = {10.1002/alz.71422}
}
Kostenlos starten →